Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878678 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL10060882 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL9958167 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL9958169 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL16508712 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL13248839 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL6877501 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL10052373 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL6876128 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4FPR2 | |
| SCHEMBL12630409 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468286-B1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2468286-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |